Many more patients with life-limiting uncontrolled seizures stand to benefit from epilepsy surgery than currently do. The biggest obstacle? A lack of referrals for surgical evaluation.
An epileptologist teams with our Center for Clinical Genomics for a pilot study that aims to use a biorepository to enable better prediction of patient-level outcomes of epilepsy surgery.
When imaging and other tests hint at a focal origin of seemingly generalized pediatric epilepsy, magnetoencephalography is the tool for detecting a potential focus — and identifying otherwise bypassed candidates for curative surgery.
This case study of an 11-year-old illustrates the pivotal role advanced imaging techniques can play in presurgical evaluation to broaden the pool of candidates for curative epilepsy surgery.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
One of the world’s premier hemispherectomy specialists looks back to epilepsy surgery’s Neolithic origins — and ahead to what blows him away about today’s neurosurgery residents.
Freedom from seizures isn’t the only outcome that matters after epilepsy surgery. Our Epilepsy Center is tracking QoL outcomes to refine selection of surgical candidates.
A Cleveland Clinic-led team will use the award to create a comprehensive risk calculator for individualized prediction of epilepsy surgery outcomes. Project leader Lara Jehi, MD, explains the value proposition.
High-resolution 7T MRI can identify otherwise unrecognizable lesions — and enable tailored SEEG electrode implantation that leads to precise localization of the epileptic zone. This case illustrates how.
How many patients who undergo epilepsy surgery achieve and maintain seizure freedom for 10 years postoperatively? This 18-year data analysis from Cleveland Clinic’s Epilepsy Center gives a sense of what’s possible.
Recent Cleveland Clinic research shows increased expression of growth associated protein 43 (GAP-43) in dysplastic neurons, and an association between increased GAP-43 expression and longer epilepsy duration in patients with type II focal cortical dysplasia. These early findings suggest that GAP-43 may prove to be a pathology-specific biomarker for epileptogenicity and progression.